The 10th Chinese H. pylori and Digestive Diseases Forum was held in Beijing on August 21-23, 2015. Established in 2006, the forum has become one of the most important platforms for scientists, gastroenterologists and clinicians in relevant areas to exchange ideas and research results on H. pylori diagnosis and treatment in China. About 800 scientists and clinicians, including 130 nationally and internationally recognized experts in digestive disease area, participated in the meeting. Professor Barry Marshall, Nobel Prize laureate in Physiology or Medicine for his discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease, participated the meeting and give a lecture. Dr. Zhenkun Ma, founder and CEO of TenNor Therapeutics was invited to give a lecture on the development of a new generation of antibiotics for H. pylori eradication.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com